[O1–12–02]: PROGRESSION FROM PRECLINICAL AD TO MCI OVER A DECADE: COGNITIVE AND BRAIN IMAGING TRAJECTORIES
Richard J. Caselli,Kewei Chen,Yinghua Chen,Pradeep Thiyyagura,Xiaoying Kuang,Robert Bauer,Cynthia M. Stonnington,Dona E. Locke,Eric M. Reiman
DOI: https://doi.org/10.1016/j.jalz.2017.07.102
2017-01-01
Abstract:To correlate the cognitive, structural, and cerebral metabolic changes that characterize the progression from preclinical Alzheimer's disease (AD) to incident mild cognitive impairment (MCI). Cognitively normal residents of Maricopa County who were at least 50 years old at entry and who reported a first degree relative with dementia underwent apolipoprotein E (APOE) genotyping. APOE e4 homozygotes were matched by age, education, and sex to one e4 heterozygote and two e4 noncarriers who were evaluated every two years with neuropsychological testing (that included the Mini-Mental Status Exam [MMSE], Auditory Verbal Learning Test [AVLT], Boston Naming Test [BNT], Judgment of Line Orientation (JLO), and Controlled Oral Word Association [COWA] tests), structural MRI, and fluorodeoxyglucose (FDG)-PET measurement of the cerebral metabolic rate for glucose (CMRgl). Over a mean interval of 13.9 years (range 10–21), 14 (11 APOE e4 carriers and 3 noncarriers) progressed to incident MCI and were compared to 32 nonprogressors (25 e4 carriers and 7 noncarriers) matched for e4 gene dose, age, followup duration, sex and education using R-package MatchControl followed over a mean interval of 19 years (range 6–21). There were no baseline differences between progressors and nonprogressors in mean age (57.9+/-4.6 years), education (15.7+/-2.0 years), sex (51.6% women), e4 carrier status (78.3% carriers), or on any neuropsychological measure (MMSE 29.7+/-0.6, AVLT recall 8.8+/-3.0, BNT 56.8+/-3.4, COWA 47.8+/-10), but annualized declines in MCI progressor scores were significantly greater (p<.0001) on the MMSE (-0.17 vs -0.01), AVLT (-0.50 vs -0.11), BNT (-0.46 vs -0.02), and COWA (-0.55 vs +0.24). With small volume correction (SVC) at p=0.05 for multiple comparisons in prespecified regions, there was significantly accelerated atrophy on MRI bilaterally in the hippocampus (p=7.72e-05), medial and lateral temporal neocortices (p=1.76e-04), and parahippocampal gyri (p=1.46e-04). Significantly accelerated CMRgl declines were observed bilaterally in posterior cingulate cortices (p=8.20e-05) and hippocampi (p=9.95e-03) as well as in the right precuneus (p=9.65e-03), all SVC corrected for multiple comparisons. Preclinical decline in cognition, cerebral structure and metabolism in individuals progressing to MCI mirrors that seen in the clinical stages of Alzheimer's disease.